PHOSPHATE
Research type
Research Study
Full title
Pragmatic randomised trial of High Or Standard PHosphAte Targets in End-stage kidney disease (PHOSPHATE)
IRAS ID
296881
Contact name
Rona Smith
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
Clinicaltrials.gov Identifier
Duration of Study in the UK
7 years, 0 months, 0 days
Research summary
Dialysis patients often have higher levels of phosphate compared with people with healthy kidneys. Research suggests that higher phosphate levels may increase the risk of heart disease and death. The current treatment guidelines suggest that high phosphate levels should be reduced towards the normal level. But evidence for these guidelines needs to be improved. Doctors don’t know if lowering blood phosphate towards a normal level is always a good option for patients receiving dialysis.
Phosphate levels can be reduced by diet, dialysis and medication. Medications used to reduce phosphate are called phosphate binders. Phosphate binder use increases the number of pills taken by dialysis patients. These medications can also cause side effects.
The study will examine whether reducing phosphate levels in dialysis patients will improve:
Life expectancy
Heart health
How patients feel or function.It is a randomised study. This means that if a patient decides to take part in the study, they will be “assigned” to either a higher or lower blood phosphate target by chance. It is up to the patient's doctor to recommend changes to their diet, adjust their dialysis prescription or prescribe phosphate binders to meet this target.
The study will include 3,600 patients from Australia, New Zealand, Canada and the UK. We expect about 2000 to be enrolled from up to 60 centres across the UK.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
21/EE/0187
Date of REC Opinion
1 Sep 2021
REC opinion
Further Information Favourable Opinion